| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0003 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.2 | 0.0003 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0005 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.18 | 0.0005 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |